Amgen Saves Patent For Making Parathyroid Drug

By Hanna Vioque ( February 10, 2025, 8:23 PM GMT) -- European officials have dismissed an appeal seeking to defeat Amgen's patent for making a peptide that treats hyperparathyroidism resulting from kidney disease, saying the patent can stand because skilled inventors at the time wouldn't have thought of linking molecules in the same way. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as